SEPN vs VKTX: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

VKTX is the larger of the two ($3.71B market cap): the incumbent the market prices for continued execution (-5.58x forward earnings, beta 0.75). SEPN is the smaller challenger ($2.39B), priced similarly on forward earnings (-26.72x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

SEPN vs VKTX: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricSEPNVKTXWhat it tells you
Market cap$2.39B$3.71BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-26.72-5.58Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range97% of range27% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.666.30How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how SEPN and VKTX affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SEPN and VKTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SEPN and VKTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Septerna (SEPN) do?

Septerna, Inc. designs oral small molecule drugs against G protein-coupled receptors, the receptor family that sits behind roughly a third of approved medicines but which has historically been drugged with injectables or with molecules found by luck rather than by design. Its Native Complex Platform reconstitutes GPCRs outside the cell in a form stable enough to screen and to solve structurally, which is what lets the company go after targets that are usually reached with peptides or antibodies. Three efforts define the pipeline in 2026: SEP-631, an oral MRGPRX2 antagonist aimed at chronic spontaneous urticaria; SEP-479, a next-generation oral PTH1R agonist for hypoparathyroidism; and a global collaboration with Novo Nordisk on oral GPCR programs in obesity, type 2 diabetes and other cardiometabolic disease. The company listed on the Nasdaq in October 2024 with an upsized IPO that raised about $288 million.

Full SEPN guide

What does Viking Therapeutics (VKTX) do?

Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its highest-profile program is VK2735, a dual GLP-1 and GIP receptor agonist for obesity, being developed in both injectable and oral forms, which puts Viking among the most closely watched challengers in the booming weight-loss drug market dominated by Novo Nordisk and Eli Lilly. Viking is also developing VK2809, a thyroid-hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH/MASH), VK0214 for a rare disease (X-linked adrenoleukodystrophy), and VK3019, an amylin receptor agonist. As a clinical-stage company, Viking has no approved products and generates no product revenue, funding itself from cash on its balance sheet. Headquartered in San Diego, California, VKTX is a speculative, binary biotech whose value hinges on clinical-trial outcomes and the eventual commercial path for its lead obesity drug.

Full VKTX guide

SEPN vs VKTX: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • SEPN drivers: The Novo Nordisk collaboration; SEP-631 into Phase 2b.
  • VKTX drivers: Lead obesity program (VK2735); Pipeline breadth in metabolic disease.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. For VKTX, viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary.

SEPN or VKTX: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SEPN if you believe its drivers more; VKTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SEPN and VKTX guides.

SEPN vs VKTX: the full fundamentals

SEPN. Price to sales of roughly 17 times shows up on screeners, but the denominator is partnership revenue on a recognition schedule, so the ratio does not describe a commercial business and comparing it to a specialty pharma multiple is not meaningful. The more useful framing is enterprise value: about $1.7 billion of market cap against roughly $516 million of cash and investments leaves close to $1.2 billion attributed to a pipeline whose most advanced asset is entering Phase 2b, down from about $1.7 billion in August. The nine-analyst mean target is about $54, well above the October 16, 2026 close of $36.22, and the next report is expected around November 9, 2026.

VKTX. Viking has no earnings to value on a P/E basis; the stock is priced on the probability-weighted potential of its pipeline, above all VK2735 in obesity, and on acquisition speculation. At about $3.3 billion, the market is valuing two Phase 3 obesity programs at roughly $2.8 billion above cash, while analysts' targets imply far more. Cash runway matters because the annual loss now exceeds the cash balance, so additional fundraising could dilute holders. All figures are approximate and should be verified against current filings.

Headline figures (approximate, October 2026): SEPN shows revenue (ttm) ~$99 million, essentially all collaboration revenue from Novo Nordisk rather than product sales, revenue (q2 2026) ~$26.8 million versus consensus near $19.2 million, net loss ~$24 million TTM (~$0.54 per share); Q2 2026 ~$13 million, EPS -$0.29 vs -$0.49 consensus, cash ~$516.5 million cash and investments at June 30, 2026, guided to fund operations at least into 2029; VKTX shows product revenue ~$0 (no approved products), net loss (ttm) ~$535 million; Q2 2026 ~$128 million, eps (q2 2026) -$1.10 vs -$1.21 consensus; Q3 consensus ~-$1.06, cash vs debt ~$502 million cash, ~$4 million debt (June 2026).

The bottom line: SEPN vs VKTX

SEPN and VKTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SEPN and VKTX exposure against your real portfolio. It is not an investment adviser.

Wondering how SEPN or VKTX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Septerna

Ask Walnut's AI anything about SEPN and see how it fits what you own.

FAQ

What is the difference between SEPN and VKTX?

+

Septerna, Inc. Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is SEPN or VKTX the better stock?

+

Neither is universally better. VKTX is the larger incumbent; SEPN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, SEPN or VKTX?

+

On forward P/E (as of November 2026), SEPN trades at -26.72x and VKTX at -5.58x, so SEPN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both SEPN and VKTX?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of SEPN vs VKTX?

+

SEPN: Every clinical-stage biotech carries binary risk, and here it has already been demonstrated: SEP-786 was discontinued in February 2025 after two severe cases of elevated unconjugated bilirubin, and the stock fell 47% that day. Several plaintiffs' firms announced investigations in the weeks after, which is a routine response to a drop of that size and did not produce a widely reported class action, but the episode is the clearest illustration of how this name trades on single data points. Revenue is collaboration accounting rather than product sales, so it is not a floor under the valuation, and Novo Nordisk can deprioritize programs. With roughly 46.7 million shares outstanding the float is small and daily moves of 20% in either direction are ordinary. Both target markets are contested, hypoparathyroidism by Ascendis and AstraZeneca with approved or late-stage injectables and chronic spontaneous urticaria by several biologics and oral candidates, so positive data still has to clear a commercial bar rather than an empty field. The fall from about $51 to $36.22 between August and mid-October 2026, with no adverse company news in that stretch, shows how far sentiment alone can move the shares. Analysts also expect losses to widen, to about $1.94 a share in 2027 as collaboration revenue is forecast to decline. VKTX: Viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. A single disappointing trial readout, safety signal, or regulatory setback for VK2735 could sharply reduce the stock's value. The obesity market is intensely competitive, dominated by Novo Nordisk and Eli Lilly with deep resources and manufacturing scale, and crowded with other entrants. Viking's losses widened sharply as Phase 3 work began (about $535 million over the trailing twelve months against about $502 million of cash), so it may need to raise more capital, diluting shareholders. Manufacturing, commercialization, and pricing all remain unproven. The stock has fallen about 31% in three months to near its 52-week low despite bullish analyst targets, which shows how sentiment can move independently of the pipeline. This is a high-risk position whose outcome depends on clinical and regulatory events outside investors' control.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell SEPN or VKTX; figures are approximate and dated (as of November 2026). Verify current data before investing.